References
- Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Dermatines N, Darmond O (2012) Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 12:86-95. https://doi.org/10.1186/1471-2407-12-86
- Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M (1999) Oncogenic Ras triggers cell suicide through the activation of caspase-independent cell death program in human cancer cells. Oncogene 18:2281-2290. https://doi.org/10.1038/sj.onc.1202538
- Erlandsson F, Linnman C, Ekholm S, Bentsson E, Zetterberg A (2000) A detailed analysis of cyclin A accumulation at the G1/S border in normal and transformed cell. Exp Cell Res 259:86-95. https://doi.org/10.1006/excr.2000.4889
- Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald JK, Sabatinni DM (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to AKT-FOXO and PKCalpha, but not S6K1. Dev Cell 11:859-871. https://doi.org/10.1016/j.devcel.2006.10.007
- Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JA, Chen G, Lemons JMS, Karantza V, Collar HA, DiPaola RS, Gelinas C, Rabinowitz JD, White E (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25:460-470. https://doi.org/10.1101/gad.2016311
- Hung F, Chen Y, Huang A, Hsiao Y, Yang J, Chung M, Chueh F, Lu H, Chung J (2013) Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrialdependent signaling pathways in A375.S2 human melanoma cells. Oncol Rep 29:1053-1060. https://doi.org/10.3892/or.2013.2230
- Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8:893-903.
- Kuger S, Flentje M, Djuzenova CS (2015) Simultaneous perturbation of the PAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Radiation Oncol 10:214-229. https://doi.org/10.1186/s13014-015-0514-5
- Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet J, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche' O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930. https://doi.org/10.1200/JCO.2008.21.6796
- Lee YM, Sicinski P (2006) Targeting cyclins and cyclindependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 5:2110-2114. https://doi.org/10.4161/cc.5.18.3218
- Li H, Jin X, Zhang Z, Xing Y, Kong X (2013a) Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem Funct 31:427-433. https://doi.org/10.1002/cbf.2917
- Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL (2013b) Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Toxicol Lett 220:267-276. https://doi.org/10.1016/j.toxlet.2013.04.021
- Maira S, Stauffer F, Brueggen J, Furet P, Schnell J, Fritsch C (2008) Identification and characterization of NVPBEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863. https://doi.org/10.1158/1535-7163.MCT-08-0017
- Mendoza MC, Er EE, Blenis J (2011) The RAS-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-327. https://doi.org/10.1016/j.tibs.2011.03.006
- Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. Cell 140:313-326. https://doi.org/10.1016/j.cell.2010.01.028
- Moon DG, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park SS, Cheon J (2014) NVPBEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 45:1027-1035. https://doi.org/10.3892/ijo.2014.2505
- Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864-29872. https://doi.org/10.1074/jbc.273.45.29864
- Park D, Lee Y (2014) Biphasic activity of chloroquine in human colorectal cancer cells. Dev Reprod 18:225-231. https://doi.org/10.12717/DR.2014.18.4.225
- Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Cofee EM, Sinamon MJ, Lee L, Chen P, Bronson RT, Martin ES, Hung KE (2011) The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wildtype colorectal cancer. PloS One 6:1-10.
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307:1098-1101. https://doi.org/10.1126/science.1106148
- Sasaki K, Tsuno NH, Sunami E, Tsrita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, Kitayama J, Takahashi K, Nagawa H (2010) Chloroquine potenntiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10:370-381. https://doi.org/10.1186/1471-2407-10-370
- Schult C, Dahlhaus M, Glass A, Fisher K, Lange S, Freund M, Junghanss M (2012) The dual kinase inhibitor NVPBEZ235 in combination with cytotoxic drugs exerts antiproliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 32:463-474.
- Seitz C, Hugle M, Crisfanon S, Tchoghandjian A, Fulda S (2013) The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer 132:2682-2693. https://doi.org/10.1002/ijc.27935
- Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783. https://doi.org/10.1200/JCO.2005.03.7689
- Shigemitsu K, Tsujishita Y, Hara K, Nanahoshi M, Avruch J, Yonezawa K (1999) Regulation of translational effectors by amino acid and mammalian target of rapamycin signaling pathways. Possible involvement of autophagy in cultured hepatoma cells. J Biol Chem 274:1058-1065. https://doi.org/10.1074/jbc.274.2.1058
- Song J, Kang JH, Kang HK, Kim K, Lee S, Choi D, Park D, Lee Y (2011) Mechanism of ethanol-induced Purkinje cell death in developing rat cerebellum: its implication in apoptosis and oxidative damage. Dev Reprod 15:205-213.
- Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838-e849. https://doi.org/10.1038/cddis.2013.350
- Szakacs G, Paterson JK, Ludwig JA, Booth-Gentle C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234 https://doi.org/10.1038/nrd1984
- Takeuchi H, Kondo Y, Fujiwara K, Kanazawa T, Aoki H, Mills GB, Kondo S (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336-3346. https://doi.org/10.1158/0008-5472.CAN-04-3640
- Wolfian BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296-1310. https://doi.org/10.1053/j.gastro.2008.02.098
- Xu C, Zhao L, Yue P, Fang G, Tao H, Owonikoko TK, Ramalingam S, Khuri FR, Sun S (2011) Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12:549-555. https://doi.org/10.4161/cbt.12.6.16397
- Yang F, Qian X, Qin W, Deng R, Wu X, Qin J, Feng G, Zhou X (2013) Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLos One 8:e58879-e58889. https://doi.org/10.1371/journal.pone.0058879
- Yang P, Liu Y, Lin Y, Shun C, Wu M, Chen C (2010) Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 70:7699-7709. https://doi.org/10.1158/0008-5472.CAN-10-1626